Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Class A ordinary shares, par value US$0.0001 per share
-
Shares outstanding
-
445M
-
Number of holders
-
7
-
Total 13F shares, excl. options
-
6.09M
-
Shares change
-
+869K
-
Total reported value, excl. options
-
$171M
-
Value change
-
+$24.4M
-
Number of buys
-
3
-
Number of sells
-
-4
-
Price
-
$28.09
Significant Holders of Royalty Pharma plc - Class A ordinary shares, par value US$0.0001 per share (RPRX) as of Q4 2023
7 filings reported holding RPRX - Royalty Pharma plc - Class A ordinary shares, par value US$0.0001 per share as of Q4 2023.
Royalty Pharma plc - Class A ordinary shares, par value US$0.0001 per share (RPRX) has 7 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.09M shares
of 445M outstanding shares and own 1.37% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (46.4M shares), VANGUARD GROUP INC (38M shares), FMR LLC (31.6M shares), BlackRock Inc. (21.5M shares), BAILLIE GIFFORD & CO (17.6M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (10.9M shares), VIKING GLOBAL INVESTORS LP (10.1M shares), STATE STREET CORP (8.87M shares), JPMORGAN CHASE & CO (8.7M shares), and GEODE CAPITAL MANAGEMENT, LLC (6.37M shares).
This table shows the top 7 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.